Cemiplimab, in GOG 3016, Looks to Break New Ground for Immunotherapy in Cervical Cancer – AJMC.com Managed Markets Network
|
Cemiplimab, in GOG 3016, Looks to Break New Ground for Immunotherapy in Cervical Cancer
AJMC.com Managed Markets Network Several studies involving immunotherapy to treat cervical cancer have reached phase 2. But a phase 3 trial is under way with cemiplimab, after researchers at Regeneron saw a positive signal in a phase 1 study and opted to move immediately to a … |
